DocumentsDate added
Original article
Giorgio Maria Paul Graziano1, Giovanni Castelli2, Antonino Graziano3*
1 University of Catania Medical School Italy
2 Prof Contract University of Catania Medical School Italy
3 Aggregate Professor University of Catania, Medical School Italy Azienda, Policlinico, Department of Sciences Medical Surgery and advanced technologies “G Ingrassia”
Address reprint requests to:
*Prof Antonino Graziano, Department of Sciences Medical Surgery and advanced technologies “G Ingrassia” via S Sofia 86-Cap 95125 Catania Italy
Article citation: Graziano GMP, Castelli G, Graziano A. Vascular thoracic fibrous adipose tissue (new disease). J Pharm Biomed Sci 2016;06(07):419–424. Available at www.jpbms.info
ABSTRACT
Introduction The primary tumors of the chest wall are rare, about 2% of all cancers, and 50% are derived from soft tissue neoplasms, benign or malignant that arise at the level of the chest wall representing 2% of all cancers; the study reports a recent observation of primitive thoracic neoplasia, and discusses the diagnosis and treatment of cancer.
Materials and Methods Paz 49 sex male has come to our attention in February 2016 at The Second Surgical Clinic of the University of Catania. The clinical history of the patient showed the presence in the dorsal thorax Ds, the formation presents a cranium caudal extension of about 190 mm, a lateral-lateral diameter of about 120 mm and an anteroposterior diameter of about 50 mm displaces posteriorly and the trapezius the latissimus dorsi and contracted close relations of contiguity with paraspinal muscles. It presents heterogeneous signal in T1 and T2.
Results The specifications with the different methods of imaging the face of a patient with expansive lesion that presented palpable mass in rapid growth (2), has been that of the identification of the lesion, with a spatial evaluation, typing, directing toward a diagnostic orientation of probable kindness.
Discussion The computed tomography (CT) allows in most cases the differential diagnosis of a neoplasm of the chest wall and defines its characteristics, the origin (in the case of the wall intrusive tumors by contiguity), the location, and the relationships with surrounding structures (Fig. 1). It also allows a more accurate staging. The choice of surgical strategy suffers first objective to be achieved: the radical or palliation.
Conclusion The described chest wall neoplasm is an example of how the pathologic classification is rapidly evolving thanks to new diagnostic techniques the therapeutic choices of benign primary lesions that generally occur as formations in sharp and regular margins, with a growth pattern of expansive and slow type. In the light of the latest findings in relation to the characteristics of important seat adipose tissue of adult stem cells, which are highly multidifferent, it is possible that if the cells are subjected to various types of stimuli can hypothesize and verify the activation to malignancy in time. The initiated research is that through an analysis of the lesion and on misuse formations mainly fat is it possible to get a review of the criteria in benign adipose tissue tumors.
KEYWORDS chest wall tumor treatment, vascular thoracic fibrous, cancer
REFERENCES
1.De Alava E, Pardo J. Ewing tumor: tumor biology and clinical applications. Int J Surg Pathol. 2001;9:717.
2.Sandberg AA. Cytogenetics and molecular genetics of bone and soft-tissue tumors. Am J Med Genet. 2002;115:189–193.
3.Rosai J. Special techniques in surgical pathology. In: Rosai J. (Ed) Rosai and Ackerman’s Surgical Pathology. 9th Ed. Edinbrough, CV Mosby. 2004:37–91.
4.Askin FB, Rosai J, Sibley RK, Dehner LP, McAllister WH. Malignant small cell tomor of the thoracopulmonary region in childhood. A distinctive clinicopathologic entity of uncertain histogenesis.Cancer. 1979;43:2438–2451.
5.A Colombo et al attività cellule staminali bollettino soc medico Pavia vol 214, 2011.
6.Kim SY, Lee JS, Ro JY, Gay ML, Hong WK, Hittleman WN. Interphase cytogenetics in paraffin sections of lung tumors by non-isotopic in situ hybridization. Mapping genotype/ fenotype heterogeneity. Am J Pathol. 1993;142:307–317.
7.Vassilopoulos PP, Voros DN, Kelessis NG, Apostolikas NG. Unusual spread of liposarcoma. Anticancer Res. 2001;21: 1419–1422.
8.Virkus WW, Mollabashy A, Reith JD, Zlotecki RA, Berrey BH,Scarborough MT. Preoperative radiotherapy in the treatment of soft tissue sarcomas. Clin Orthop Relat Res. 2002;397:177–189.
9.Layfield LJ ed. Lipomatous Neoplasms. In Cytopathology of Bone and Soft Tissue Tumors. Oxford, 2002, Oxford University Press, pp 71–88.
10.Christopher DM, Unni KK, Mertens F. WHO classification of tumors. Pathology and genetics: tumors of soft tissue and bone.Lyon, France, 2002, IARC Press, 35–46.
11.Wolman SR. Fluorescence in situ hybridisation. A new tool for the pathologist. Hum Pathol. 1994;25:586–590.
12.Grady WW, Cheng L, Lewin KJ. Application of in situ DNA hybridization technology to diagnostic surgical pathology. Pathol Annu. 1987;22:151–175.
13.Houldsworth J, Chaganti RS. Comparative genomic hybridization. An overview. Am J Pathol. 1994;145:1253–1260.
14.Naber SP, Smith LL Jr, Wolfe HJ. Role of frozen tissue bank in molecular pathology. Diagn Mol Pathol. 1992;1:73–79.
15.Mies C, Houldsworth J, Chaganti RS. Extraction of DNA from paraffin blocks for Southern blot analysis. Am J Surg Pathol. 1991;15:169–174.
16.Erlich HA, Gelfand D, Sninsky JJ. Recent advances in the polymerase chain reaction. Science. 1991;252:1643–1651.
17.Heller MJ. DNA microarray technology: devices, systems, and applications. Annu Rev Biomed Eng. 2002;4:129–153.
18.Bertucci F, Viens P, Tagett R, Nguyen C, Houlgatte R, Birnbaum D. DNA arrays in clinical oncology: promises and challenges. Lab Invest. 2003;83:305–316.
19.Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors– a sub group of small-roundcell tumors defined by specific chimeric transcripts. N Engl J Med. 1994;331:294–299.
20.Kumar S, Pack S, Kumar D, Walker R, Quezado M, Zhuang Z, et al. Detection of EWS-FLI-1 fusion in Ewing’s sarcoma/ peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue. Hum Pathol. 1999;30:324–330.
21.Kumar S, Pelman E, Haris CA, Raffeld M, Tsokos M. Myogenin is a specific marker for rhabdomyosarcomas: an immunohistochemical study on paraffin-embedded tissues. Mod Pathol. 2001;13:988–993.
22.Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicatorsin alveolar rhabdomyosarcoma: a report from the chidren’s oncology group. J Clin Oncol. 2002;20:2672–2679.
23.Isihda M, Miyamoto M, Naitoh S, Tatsuda D, Hasegawa T, Nemoto T, et al. The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma. Mol Cell Biol. 2007;27:1348–1355.
24.Patricia M. McCormack, “Surgical management of chest wall tumors”, In: Arther E. Baue, Alexander S. Geha, Graeme L. Hammond, Hillel Lacks, Keith S. Naunhiem, Glenn’s Thoracic and Cardiovascular Surgery, 6th edition, Appleton and Lange.1990;593–607.
25.Kamal A, Mansour MD, Vinod H, Thourani MD, Albert Losken MD, Jamis G, et al. Chest wall resection and reconstruction: A 25 year experience. Ann Thorac Surg. 2002;73(1):720–726.
26.Graeber GM, Langenfeld J. Chest wall resection and reconstruction,In: Franco KL, Putman JR, eds. Advanced therapy in thoracic surgery. London: BC Decker, 1998;175–185.
27.Cavallaro A, Giorgio MPG, Cavallaro M, Graziano A. The neuroendocrine cancer personal comments and operational remarks. J Surg Surg Res. 2015;1:53–58.
28.Graeber GM. Chest wall resection and reconstruction. Semin Thorac Cardiovasc Surg. 1999;11(3):251–263.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflicts of interest: The authors have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
ORIGINAL ARTICLE
Shrikant Gorakshnath Jadhav1,Vivek Viswanathan2,Alka Pravin Mukne2*
1Department of Pharmaceutical Analysis, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai, Maharashtra, India
2Department of Pharmacognosy and Phytochemistry, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai, Maharashtra, India
Address reprint requests to:
*Dr. Alka Pravin Mukne, Department of Pharmacognosy and Phytochemistry, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai, Maharashtra, India
Article citation: Jadhav SG, Viswanathan V, Mukne AP. Validated HPTLC method for simultaneous quantification of isoniazid, rifampicin and glabridin. J Pharm
Biomed Sci 2016;06(07):453–459.Available at www.jpbms.info
ABSTRACT
A new, rapid and simple high performance thin layer chromatography technique for the simultaneous quantification of isoniazid, rifampicin and glabridin in combination is developed and validated. The method was developed by separating the constituents in pre-coated silica gel 60 F254 aluminium plate. The mobile phase for separation consisted of ethanol, ethyl acetate, dichloromethane and chloroform. The densitometric scanning of the plates post development was done at 254 nm which gave retention factors of 0.28 ± 0.005, 0.38 ± 0.007 and 0.75 ± 0.008 for isoniazid, rifampicin and glabridin respectively. The method was validated as per International Conference on Harmonization (ICH) for linearity, precision (repeatability and intermediate precision), accuracy, robustness, limit of detection and limit of quantification. The responses were found to be linear in the range of 200–400 ng/band for isoniazid and rifampicin, whereas the range was 400–800 ng/band for glabridin. Statistical analysis showed acceptable limits for precision, accuracy and robustness. Limit of detection and limit of quantification values for all the three drugs were estimated by signal to noise ratio method.
KEYWORDS glabridin, high performance thin layer chromatography, ICH, isoniazid, rifampicin, validation
REFERENCES:
1.Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ. 2008;336:484–487.
2.Simmler C, Pauli GF, Chen SN. Phytochemistry and biological properties of glabridin. Fitoterapia. 2013;90:160–184.
3.Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Antimicrobial activity of licorice flavonoids against methicillin-resistant Staphylococcus aureus. Fitoterapia. 2002; 73:536–539.
4.Mitscher LA, Park YH, Clark D, Beal JL. Antimicrobial agents from higher plants. Antimicrobial isoflavanoids and related substances from Glycyrrhiza glabra L. var. Typica. J Nat Prod.1980;43:259–269.
5.Gupta VK, Fatima A, Faridi U, Negi AS, Shanker K, Kumar JK,et al. Antimicrobial potential of Glycyrrhiza glabra roots.J Ethnopharmacol. 2008;116:377–380.
6.Nair SS, Pharande RR, Bannalikar AS, Mukne AP. In vitro antimycobacterial activity of acetone extract of Glycyrrhiza glabra. J Pharm Pharmacogn Res. 2015;3:80–86.
7.Tim Cushnie TP, Lamb AJ. Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Ag.2011;38:99–107.
8.De La Iglesia AI, Morbidoni HR. Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends. Revista Argentina de Microbiologia. 2006;38:97–109.
9.Korhalkar A, Deshpande M, Lele P, Modak M. Antimicrobial activity of Yashtimadhu (Glycyrrhiza glabra L.) – A Review. Int J Curr Microbiol App Sc. 2014;3:329–336.
10.Glass BD, Agatonovic-Kustrin S, Chen YJ, Wisch MH. Optimization of a stability-indicating hplc method for the simultaneous determination of rifampicin, isoniazid, and pyrazinamide in a fixed-dose combination using artificial neural networks. J Chrom Sc. 2007;45:38–44.
11.Shah U, Jasani A. UV Spectrophotometric and RP-HPLC methods for simultaneous estimation of Isoniazid, Rifampicin and Piperine in pharmaceutical dosage form. Int J Pharm Pharmaceutical Sc. 2014;6:274–280.
12.Shah Y, Khanna S, Jindal KC, Dighe VS. Determination of rifampicin and isoniazid in pharmaceutical formulations by HPLC; Drug Dev. Ind Pharm. 1992;18:1589–1596.
13.Ali J, Ali N, Sultana Y, Baboota S, Faiyaz S. Development and validation of a stability-indicating HPTLC method for analysis of antitubercular drugs. Acta Chromatographia. 2007;18:168–179.
14.Sharma SC, Das S, Talwar SK. Spectrophotometric estimation of Rifampin-Isoniazid mixture in dosage form. J Assoc Off Anal Chem. 1987;70:679–681.
15.Arifa Begum SK, Basava Raju D, Rama Rao N. Simultaneous estimationof rifampicin and isoniazid in combined dosage form by a simple UV spectrophotometric method. Der Pharmacia Lett.2013;5:419–426.
16.Manna A, Ghosh I, Datta S, Ghosh PK, Ghosh LK, Gupta BK.Simultaneous estimation of isoniazid and rifampicin in combine dosage form. Ind J Pharm Sc. 2000;62:185–186.
17.Patil JS, Sarasija S, Sureshbabu AR, Rajesh MS. Development and validation of liquid chromatography-mass spectrometry method for the estimation of Rifampicin in plasma. Ind J Pharm Sc. 2011;73:558–563.
18.Srivastava A, Waterhouse D, Ardrey A, Ward SA. Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic–tandem mass spectrometric method. J Pharm Biomed Anal. 2012;70:523–528.
19.Shanker K, Fatima A, Negi AS, Gupta VK, Darokar MP, Gupta MM, et al. RP-HPLC Method for the Quantitation of Glabridin in Yashti-madhu (Glycyrrhiza glabra). Chromatographia. 2007;65:771–774.
20.Kamal YT, Singh M, Tamboli ET, Parveen R, Arif Zaidi SM, Ahmad S. Rapid RP-HPLC Method for the Quantification of glabridin in crude drug and in polyherbal formulation. J Chrom Sc. 2012;50:779–784.
21.Viswanathan V, Mukne AP. Development and validation of HPLC and HPTLC methods for estimation of gabridin in extracts of Glycyrrhiza glabra. J AOAC Int. 2016;99(2):374–379.
22.Singh M, Kamal YT, Tamboli ET, Parveen R, Ansari SH, Ahmad S. Glabridin, a Stable Flavonoid of Glycyrrhiza glabra: HPTLC analysis of the traditional formulation. J Planar Chrom. 2013;26:267–273.
23.Aoki F, Nakagawa K, Tanaka A, Matsuzaki K, Arai N, Mae T. Determination of glabridin in human plasma by solid-phase extraction and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;828:70–74.
24.ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2 (R1), Nov 2005.
25.Ranjane PN, Gandhi SV, Kadukar SS, Bothara KG. HPTLC determination of cefuroxime axetil and ornidazole in combined tablet dosage form. J Chrom Sc. 2010;48:26–28.
26.Ansari MJ, Ahmad S, Kohli K, Ali J, Khar RK. Stability-indicating HPTLC determination of curcumin in bulk drug and pharmaceutical formulations. J Pharm Biomed Anal. 2005;39:132–138.
27.Shewiyo DH, Kaale E, Risha PG, Dejaegher B, Smeyers-Verbeke J, Vander Hayden Y. HPTLC methods to assay active ingredients in pharmaceutical formulations: a review of the method development and validation steps. J Pharm Biomed Anal. 2012;66:11–23.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding:The work was supported by grant received from Department of Biotechnology, Government of India (Sanction order no. BT/PR5572/MED/29/534/2012 dated 13.06.2013).
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Samia MohamedAli Elamien1*,Omer Balla Ibrahim1,Selma Ali Albashir1
1 Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Sudan
Address reprint requests to:
*Samia MohamedAli Elamien,
Department of Chemical Pathology,Faculty of Medical Laboratory Sciences, Al Khartoum University, Sudan
Article citation: Elamien SM, Ibrahim OB, Albashir SA. The effect of pulmomary tuberculosis infection on some biochemical levels on liver and kidney tests at abu-anja hospital, sudan. J Pharm Biomed Sci 2016;06(07):410–413.
ABSTRACT
Background Pulmonary tuberculosis (TB) is associated with increased mortality and morbidity. Its exact aetiology has not been defined although several evidence indicate that various elements might play an important role in pulmonary tuberculosis changes in intracellular liver function, and renal function concentrations seem to be involved in the pathogenesis of pulmonary tuberculosis.
Objective The study was conducted to find out the role of pulmonary tuberculosis in liver and kidney impairments in newly diagnosed adult with pulmonary tuberculosis.
Methods The study group was composed of 50 newly adult diagnostic pulmonary tuberculosis(9 females and 41 males) while the group was 50 healthy individual (13 females and 37 males) controls analysed for liver function tests and renal function test by automated chemistry analysers (mind ray chemistry analyser Bs-200.
Results Both the serum liver function and renal function levels were significantly different in the pulmonary tuberculosis group as compared with the normal group.
Conclusion It can be concluded that a biochemical abnormality of liver and kidney level tests can play a significant role in the pathogenesis of pulmonary tuberculosis.
KEYWORDS pulmonary tuberculosis, liver, kidney, Abu, Anja.
REFERENCES
1.WHO Health Organization, GLOBAL Tuberculosis Control; Report 2010 in GENEUA 2010.
2.World Health organization WHO’s Global Tuberculosis Report 29 Act 2015, p. 2–4.
3.Gertz MA, Kyle RA. Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine (Baltimore). 1991;70:246–56.
4.Dixit R, Gupta R, Dave L, Prasad N, Sharma S. Clinical profile of patients having pulmonary tuberculosis and renal amyloidosis.Lung India. 2009;26(2):41–45.
5.Morris CD, Bird AR, Nell H. The hematological and biochemical changes in severe pulmonary tuberculosis. Q J Med. 1989;73(3):1151–1159.
6.WHO: GLOBAL Tuberculosis Control: Epidemiology, Strategy, Financing. 2009: pp. 7–46.
7.Mohammed OA, Muhammad HG. Alshammery College of Medicine University of Babylon, Hillah, Iraq. Med J Babylon. 2011;8(4).
8.Karyadi E, West CE, Schultink W, Nelwan RH, Gross R, Amin Z, et al. A double blind, placebo-controlled study of vitamin A and Zinc supplementation in persons with tuberculosis in Indonesia: effect on clinical response and nutritional status. Am J Clin Nutr. 2002;75:720–727.
9.Klote MM, Agodoa LY, Abbott KC. Risk factors for Mycobacterium tuberculosis in US chronic dialysis patients. Nephrol Dial Transplant. 2006;21(11):3287–92.
10.Conte G, Iavarone M, Santorelli V, De Nicola L. Acute renal failure of unknown origin. Don’t forget renal tuberculosis. Nephrol Dial Transplant. 1997;1260–1261.
11.Onwuliri VA. Total bilirubin, albumin, electrolytes and anion gap in HIV positive patient in Nigeria. J Med Sci. 2004;4(3):214–220.
12.Maity SG. Hepatobiliary tuberculosis–Therapeutic challenge, medicine up date 2005, p. 485-487.
13.Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme condition in Singapore. Int J Tuberc Lung Dis. 2002;6:699–705.
14.Burits C, Ashwood E, David B. Tietiz Text Book of Clinical Chemistry. 4th Edition. (1999) W.B, Saunders Comp. U.S.A.
15.Szeto YT, Kwok TC, Benzie IF. Effects of a long-term vegetarian diet on biomarkers of antioxidant status and cardiovascular disease risk. Nutrition. 2004;20(10):863–6.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
ORIGINAL ARTICLE
Preeti B Agrawal*,Divyesh Goswami,Sajjan S Surana,Sujanani Shashi
Department of Pathology, Pacific Medical College and Hospital, Udaipur Rajasthan,India
Address reprint requests to:
*Dr Preeti B Agrawal, 174/A,P Road, Bhupalpura, Udaipur 313001,Rajasthan, India
Article citation: Agrawal PB, Goswami D, Surana SS, Shashi S. Pre-donation deferral of blood donors in tertiary care hospital attached to medical college in Southern Rajasthan. J Pharm Biomed Sci 2016;06(07):460–463. Available at www.jpbms.info
ABSTRACT
Purpose The primary objective of this study is to record and document the current rate and reason for donor deferral in our tertiary care hospital in Southern Rajasthan.
Method A retrospective study of donors was carried out from the donor records in the blood bank of a tertiary hospital during period of April 2014 to April 2016. Detailed information of the donor deferral was recorded from deferral register. We used statistical method to detect the rate and reason for donor deferral.
Result and Conclusion Every blood bank should analyze the reasons of deferral amongst blood donors and utilize this analysis for addressing the issue and ameliorating the cause of deferral if possible.
KEYWORDS blood donor, deferred donor, NACO, SBTC, Pre-donation deferral
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
ORIGINAL ARTICLE
YashPaul Dev Sharma,Preetinder Singh*,Raghav Yashbir,Kaur Manvir,Sharma Shivli,Wahi Ankur
Department of Periodontology and Oral Implantology, Swami Devi Dyal Hospital and Dental College, Barwala, Panchkula
Address reprint requests to:
*Preetinder Singh, Department of Periodontology and Oral Implantology,Swami Devi Dyal Hospital and Dental College, Barwala, Panchkula
Article citation: Sharma YD, Singh P, Yashbir R, Manvir K, Shivli S, Ankur W. Outcome of vitamin D supplementation on Implant osseointegration in patients suffering from chronic kidney disease: a prospective randomized study. J Pharm Biomed Sci 2016;06(07):445–452. Available at www.jpbms.info
ABSTRACT
Aim This study was aimed to investigate the effect of Vit D supplementation on implant osseointegration in CKD.
Settings and Design This was a prospective randomized study conducted on 20 patients with complaint of missing teeth and who had chronic kidney disease. After evaluation of the medical reports of the patients; medical consultancy was taken from the physician.
Materials and Methods Out of twenty patients ten were given vitamin D supplements (60,000 IU). Implants were placed under aseptic conditions. The following radiographic and clinical parameters were evaluated-1) Height of crestal bone. 2) Implant mobility. 3) Papilla fill index. 4) bleeding on probing.
Statistical Analysis Used The results were compiled and statistically analyzed using SPSS Version 19 Version. The Mann–Whitney U Test was used for the intergroup comparison and Wilcoxon Sign Rank Test for the intra-group comparison.
Results Statistically, significant results were seen in Group I, which were on vitamin D supplementation in relation to osseointegration when compared to group II. It demonstrated that weekly supplementation with 60,000 IU of cholecalciferol for 12 weeks is an effective way of correcting vitamin D status in patients with CKD stage 3 and 4 which also, helps in the formation of bone for osseointegration.
Conclusion Implants placed in patients with CKD on vitamin D supplementation were more successfully osseointegrated and functional, which was confirmed clinically and radiographically.
KEYWORDS dental implants; chronic kidney diseases; bone mineralization; osseointegration; parathyroid hormone (PTH)
REFERENCES:
1.Marakoglu I, Gursoy UK, Demirer S, Sezer H. Periodontal status of chronic renal failure patients receiving hemodialysis. Yonsei Med J. 2003;44(4):648–52.
2.Brasil. Ministério da Saúde. Painel de Indicadores do SUSNº7. Departamento de Monitoramento e Avaliação do SUS/ Secretaria de Gestão Estratégica e Participativa. Brasília, DF;2010.
3.Gonçalves EM, Karam LALL, Milfont TS, Araújo MD, Santana JML, Lima DLF. Prevalência de periodontite em pacientes submetidos a hemodiálise. J Bras Nefrol. 2007;29(3):115–9.
4.Pelletier S, Chapurlat R. Optimizing bone health in chronic kidney disease. Maturitas. 2010;65:325–33.
5.Ott SM. Bone disease in CKD. Curr Opin Nephrol Hypertens.2012;21:376–81.
6.Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Kidney Disease: Improving Global Outcomes(KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease:Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–53.
7.KDIGO. Clinical practice guideline for the diagnosis, evaluation,prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl.2009;S1–S130.
8.Lee MM, Chu EY, El-Abbadi MM, Foster BL, Tompkins KA, Giachelli CM, Somerman MJ. Characterization of mandibular bone in a mouse model of chronic kidney disease. J Periodontol.2010; 81:300–9.
9.Craig RG, Kotanko P, Kamer AR, Levin NW. Periodontal diseases–a modifiable source of systemic inflammation for the end-stage renal disease patient on haemodialysis therapy? Nephrol Dial Transplant. 2007; 22:312–5.
10.Stellingsma C, Vissink A, Meijer HJ, Kuiper C, Raghoebar GM.Implantology and the severely resorbed edentulous mandible. Crit Rev Oral Biol Med. 2004;15:240–8.
11.Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M,Kawagishi T, et al. Serum levels of 1,25-dihydroxyvitamin D,24,25-dihydroxyvitaminD, and 25- hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999;55:1019–27.
12.González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. American journal of nephrology.2004;24:503–10.
13.Rouached M, El Kadiri Boutchich S, Al Rifai AM, Garabedian M,Fournier A. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int.2008;74:389–90.
14.Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W,Someren JT, et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008;14:10–17.
15.LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, et al.Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis.2005;45:1026–33.
16.Brinker MR, O’Connor DP, Monla YT, Earthman TP. Metabolic and endocrine abnormalities in patients with nonunions. J Orthop Trauma. 2007;21:557–70.
17.Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4–8.
18.Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104.
19.Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73:1345–54.
20.Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.
21.Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, Donald J,et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21:1371–80.
22.Kelly J, Lin A, Wang CJ, Park S, Nishimura I. Vitamin D and bone physiology: demonstration of vitamin D deficiency in an implant osseointegration rat model. J Prosthodont. 2009;18:473–78.
23.Alvim-Pereira F, Montes CC, Thomé G, Olandoski M, Trevilatto PC. Analysis of association of clinical aspects and vitamin D receptor gene polymorphism with dental implant loss. Clin Oral Implants Res. 2008;19:786–95.
24.Jingushi S, Iwaki A, Higuchi O, Azuma Y, Ohta T, Shida JI, et al.Serum 1alpha,25-dihydroxyvitamin D3 accumulates into the fracture callus during rat femoral fracture healing. Endocrinology.139:1467–73.
25.Xu B, Zhang J, Brewer E, Tu Q, Yu L, Tang J, et al. Osterix enhances BMSC associated osseointegration of implants. J Dent Res. 2009;88:1003–07.
26.Mombelli A, van Oosten MAC, Schu¨r ch E, Lang NP. The microbiota associated with successful or failing osseointegrated titanium implants. Oral Microbiol Immunol. 1987;2:145–15.
27.Wasserman BH, Geiger AM, Turgeon LR. Relationship of occlusion and periodontal disease: VII. Mobility. J Periodontol. 1973;44:572–78.
28.Jemt T. Regeneration of papillae after single-implant treatment.Int J Periodontics Restorative Dent. 1997;17:327–33.
29.Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with endstage renal disease. Kidney Int. 2000;58:396–99.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.